Hemophilia A and hemophilia B are hereditary, X-chromosomal, recessive bleeding disorders caused by deficiency or absence of coagulation factors VIII or IX. The incidence of HA is estimated to be 1 in 5,000 males, whereas that of HB is 1 in 30,000 males. (Stonebraker, 2010; 2012) The disorders are classified into three categories according to the coagulation factor activity present in blood: severe (<0.01 IU/dL), moderate (0.01-0.05 IU/dL), and mild (0.06-0.40 IU/dL). (Kumar, 2013) Children with severe hemophilia typically develop spontaneous and recurrent bleeds, most commonly into joints (hemarthrosis) and muscles, whereas those with mildmoderate hemophilia tend to experience bleeding related to trauma or surgery. Clinical manifestations of HA and HB are identical. The first bleeding occur already in the neonatal period as a massive cephalhematoma, prolonged bleeding from the umbilical cord or after circumcision. When a child begins to crawl, stand and walk, bleeding most commonly affects weight-bearing joints and muscles. As a result of reccurent and untreated hemarthroses develops hemophilic arthropathy and severe deformities. The diagnosis is suspected in a patients with an elevated APTT and normal PT and platelet count. It is confirmed by specific factor assays. The most common and the most serious complication is the development of inhibitors whose treatment is difficult. Prophylactic treatment with recombinant FVIII or FIX is now the standard of care for children with severe and moderate hemophilia.